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Experimental Section 
Materials: Gelatin (type A, from porcine skin), sorbitan monooleate (Span® 80), and toluene 
(99.8%) were all obtained from Sigma-Aldrich and used as received for fabricating the gelatin 
microspheres with uniform sizes. PLGA (lactide:glycolide = 50:50 and 75:25), and 1,4-dioxane 
(99.8%) were also obtained from Sigma-Aldrich and used as received for fabricating the 
scaffolds. The water used in all fabrications was obtained by filtering through a set of cartridges 
(Millipore). 
Preparation of inverse opal scaffolds: PLGA inverse opal scaffolds were fabricated 
according to our previously reported protocols.[1b, 6c, 6d, 9] Briefly, uniform gelatin microspheres 
(about 1.5 wt.%) were collected as a suspension in methanol in a 50-mL centrifuge tube. The 
tube was gently tapped to pack the microspheres into a cubic close-packed lattice. The lattice 
was placed in an oven heated at 70 oC for 1 h to induce necking between the adjacent 
microspheres. After cooling to room temperature, the lattice was carefully harvested using a 
spatula, placed on a filter paper to remove methanol, and then infiltrated with a PLGA solution in 
1,4-dioxane (30 wt.%, containing a mass ratio of 1:1 of the two types of PLGAs, 50:50 and 
75:25). After removing the excess PLGA solution with filter paper, the pellet containing PLGA 
solution was frozen in a refrigerator (-20 oC) for 5 h, and then lyophilized in a freeze-dryer 
(Labconco) overnight. The sample was immersed in ethanol, vacuumed briefly to eliminate air 
bubbles trapped in the sample, and placed in 900 mL of water heated at 45 oC under magnetic 
stirring for 3–4 h to dissolve the gelatin microspheres. To fabricate formazan-doped scaffolds, 
0.5 wt.% (i.e., 1.67 wt.% to PLGA) MTT formazan (Sigma-Aldrich) was added into the PLGA 
solution in 1,4-dioxane and this solution was used to infiltrate the gelatin lattice. All the other 
procedures were kept the same as for making plain scaffolds. The scaffolds were then stored in 
PBS (Invitrogen) prior to use. 
Animals and implantation of scaffolds: All animal experiments were performed in 
accordance with protocols approved by the Washington University Department of Comparative 
Medicine and the Animal Studies Committee. Athymic nude mice 4–5 weeks old were obtained 
from Harlan and housed under specific pathogen-free conditions in the animal facility at 
Washington University. All the scaffolds were sterilized in 70% ethanol for at least 2 h prior to 
implantation. The scaffolds were then implanted subcutaneously in the ears of the mice.[6c] 
Briefly, animals in all groups were anesthetized by administration of gaseous isoflurane (2%, 
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Butler Inc., Dublin) and aseptically prepared. One parasagittal incision was made on the top side 
of the ear of each animal approximately 0.5 cm to the head. Subcutaneous pockets were created 
lateral to the incision by using blunt dissection. One scaffold was inserted into the subcutaneous 
pocket using a pair of tweezers (one scaffold per mouse). The skin incision was then closed with 
9-0 Ethilon suture (Ethicon) and secured using GLUture topical tissue adhesive (Abott 
Laboratories). 
Degradation of inverse opal scaffolds: For in vitro experiments, inverse opal scaffolds 
immersed in 5 mL of either PBS or PBS containing 0.025 wt.% lipase (Sigma-Aldrich) at 37 oC. 
The medium was changed every day. One group of scaffolds (N = 4) was fixed onto glass slides 
using a small amount of epoxy (one scaffold per slide), and was subjected to non-invasive PAM 
imaging. The scaffolds in the other group (N = 3 for each time point) were used for mass loss 
measurement. Briefly, three scaffolds were removed from the medium each week, washed 
thoroughly with water, and allowed to air-dry. The mass of each dry scaffold was measured 
using a microbalance (Cahn C-30), then, each scaffold was dissolved in 0.2 mL 1,4-dioxane, and 
absorbance at 562 nm was obtained by a spectrophotometer (Tecan Infinite 200). The amount of 
MTT formazan was calculated according to a calibration curve. For in vivo experiments, one 
group of implanted scaffolds (N = 3) was monitored non-invasively using PAM, and the 
scaffolds in the other group (N = 3 for each time point) were used for mass loss measurement. 
Three scaffolds were explanted each week and freeze-dried. Each scaffold/tissue construct was 
dissolved in dichloromethane (DCM), and the insoluble parts were removed by centrifugation. 
The DCM solution containing dissolved PLGA was freeze-dried and the mass was measured 
using a microbalance. To determine the background mass caused by soluble tissue components, 
ear tissue samples with approximately the same volume were subjected to the same analysis. 
Photoacoustic microscopy (PAM) and signal processing: Two PAM systems were used for 
this study: optical-resolution PAM (OR-PAM) and acoustic-resolution PAM (AR-PAM). For 
PAM, the optical and ultrasonic foci are configured coaxially and confocally. For the OR-PAM, 
the optical focal spot size was approximately 5 µm, much smaller in diameter than the acoustic 
focus, so the lateral resolution was predominantly determined by the optical focal spot size, the 
so-called optical resolution. For the AR-PAM, the optical focal spot size was 2 mm in diameter 
in a clear medium, much larger than the ultrasonic focus, so the lateral resolution was 
predominantly determined by the ultrasonic focus, the so-called acoustic resolution. 
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OR-PAM was used to monitor the degradation of scaffolds in vitro.[13] Briefly, The 
nanosecond pulsed laser beam from a tunable dye laser (CBR-D, Sirah) pumped by a Nd:YLF 
laser (INNOSLAB, Edgewave) was tightly focused into the sample by an optical objective (NA 
= 0.1 in air). An optical-acoustic beam combiner composed of a layer of silicone oil sandwiched 
by two prisms was used for the coaxial and confocal alignment of the optical illumination and 
acoustic detection. The resultant ultrasound waves were first focused by a concave acoustic lens 
(NA = 0.5 in water) ground into the bottom of the combiner, and then detected by a wideband 
ultrasonic transducer (V214-BB-RM, Olympus-NDT), which had a central frequency of 50 MHz 
and a 6-dB nominal bandwidth of 70%. A correction lens offset the optical aberration of the 
prism. The OR-PAM could achieve a lateral resolution of approximately 5 µm, an axial 
resolution of approximately15 µm, and a penetration depth of about 1 mm. 
AR-PAM was used to monitor the degradation of scaffolds in vivo.[14] Briefly, optical 
excitation was provided by the same laser system as for OR-PAM, and the photoacoustic signals 
were detected using an ultrasonic transducer. The light was coupled into a multimode optical 
fiber (M30L02, Thorlabs) and reshaped by a conical lens to form a ring pattern on the tissue 
surface. The ring-shaped light pattern was then weakly focused into the sample by an optical 
condenser, the light focus overlapped with the tight detection ultrasonic focus. The AR-PAM 
could achieve a lateral resolution of approximately 45 µm, an axial resolution of approximately 
15 µm, and a penetration depth of about 3 mm, when an ultrasonic transducer with a central 
frequency of 50 MHz was used. Alternatively, when using an ultrasonic transducer with a central 
frequency of 20 MHz, the AR-PAM had a lateral resolution of approximately 80 µm, an axial 
resolution of approximately 30 µm, and a penetration depth of up to 5–10 mm. 
All volumetric data were processed using custom MATLAB (Mathworks) programs. 
Scanning electron microscopy (SEM): SEM (Nova NanoSEM 2300, FEI) was used to 
characterize the gelatin lattices and the PLGA inverse opal scaffolds. Prior to imaging, the 
samples were sputtered with gold for 60 s. Images were taken at an accelerating voltage of 5 kV. 
Statistics: All the results were presented as mean ± standard error for each experimental 
group. Four scaffolds were monitored for in vitro PAM imaging, and the other three scaffolds 
were used for mass measurement at each time point. Three mice were monitored for in vivo 
PAM imaging, and the other three mice were sacrificed for histology analyses at each time point. 
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Figure S1. Degradation of pristine and MTT formazan-doped PLGA inverse opal scaffolds in 
PBS and lipase solution, as measured by the mass loss assay. The addition of MTT formazan did 
not alter the degradation profiles of the scaffolds. 
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Figure S2. a) The change in the mass of MTT formazan as a function of degradation time for the 
scaffolds in PBS, in the absence and presence of lipase, respectively. b) The change in the mass 
percentage of MTT formazan relative to the scaffolds as a function of degradation time of the 
scaffolds in PBS, in the absence and presence of lipase, respectively. The amount of MTT 
formazan remained almost unchanged during the period of 6 weeks, indicating that essentially no 
dye leaked out from the scaffold during incubation. 
 
6 
 
 
 
Figure S3. An OR-PAM MAP image of a PLGA inverse opal scaffold doped with MTT 
formazan, showing the uniform pores and interconnecting windows. The image was color-coded 
by depth of maximum. MAP stands for “maximum amplitude projection”. 
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Figure S4. A coronal AR-PAM MAP image of a PLGA inverse opal scaffold doped with MTT 
formazan, showing the porous structure. MAP stands for “maximum amplitude projection”. 
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Figure S5. Coronal AR-PAM MAP images separately showing the implanted PLGA inverse 
opal scaffold and the blood vessels in the ear of a nude mouse at weeks 0, 1, 3, and 6 post 
implantation. MAP stands for “maximum amplitude projection”. 
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Figure S6. a–c) Coronal (top row) and sagittal (bottom row) PAM MAP images showing the 
PLGA inverse opal scaffold subcutaneously implanted at the dorsal site of a nude mouse, at 
week 2 post implantation, with (a) 0, (b) 1, and (c) 2 layers of chicken breast overlaid on top of 
the skin. MAP stands for “maximum amplitude projection”. 
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Figure S7. Coronal (top row) and sagittal (bottom row) PAM MAP images showing the PLGA 
inverse opal scaffold subcutaneously implanted at the dorsal site of a nude mouse, at (a) week 2 
and (b) week 4 post implantation. MAP stands for “maximum amplitude projection”. 
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Movie S1. A 3D co-registered dual-wavelength AR-PAM movie showing the scaffold and the 
vasculature simultaneously at week 0 post implantation, in the ear of a nude mouse. 
 
Movie S2. A 3D co-registered dual-wavelength AR-PAM movie showing the scaffold and the 
vasculature simultaneously at week 1 post implantation, in the ear of a nude mouse.  
 
Movie S3. A 3D co-registered dual-wavelength AR-PAM movie showing the scaffold and the 
vasculature simultaneously at week 3 post implantation, in the ear of a nude mouse. 
 
Movie S4. A 3D co-registered dual-wavelength AR-PAM movie showing the scaffold and the 
vasculature simultaneously at week 6 post implantation, in the ear of a nude mouse. 
 
